HealthTech Innovation Days

October 5&6 2020 at the Peninsula Paris and virtually

Focus on

Contribution of Medtech and Artificial Intelligence to future innovations

Interviews of :

Gary Slack
Senior Vice President Global Medical Devices at BSI
Speaker at «New EU regulations in the Medtech sector»
Link to the replay : https://htid-paris.streameo.fr/L1.html

David Dellamonica
VP Value-based health Innovation lead Europe at Amgen
Speaker at «Unleashing the true potential of AI in Healthcare together»
Link to the replay https://htid-paris.streameo.fr/E14.html

Frederic Jean
Co-developer at Digital Medical Hub AP-HP
Speaker at «Unleashing the true potential of AI in Healthcare together»
Link to the replay https://htid-paris.streameo.fr/E14.html

Mathieu Grajoszex
Head of Digital Medical Hub AP-HP

David Caumartin
CEO at Theraclion
Moderator at «Renewed appetite for Medtech markets : VC/ Medtech duo »
Link to the replay https://htid-paris.streameo.fr/E11.html



Samuel Levy
Founding Partner at Lauxera Capital Partners
Moderator at «Medtech - Market Access »
Link to the replay https://htid-paris.streameo.fr/L2.html

Contribution of Medtech and Artificial Intelligence to future innovations

New EU regulations in the Medtech Sector

Gary Slack, Senior Vice President Global Medical Devices at **BSI**

«The biggest change since 30 years ... think early and don't leave it too late !»

The Medical Device regulation and the IVD regulation are significant changes in European regulation. It's the biggest change since the original medical device directive in 1993. Realistically, what I would suggest to manufacturers is be aware the implementation date of May 2021 is very close. Whilst there's a transition period to 2024, if manufacturers leave it until, 2022 or 2023 to apply, I think they run a significant risk of running into problems in terms of timing, as the capacity within the European notified body system is challenged. So, I would say think early and don't leave it too late, leaving it to 2023 or early 2024 would be a huge risk for a manufacturer. And they could lose access to European markets.
The second area I would focus on is ensure you open discussions and engage your notified body as early as possible. I think the more we communicate at this point the better, as we (NB's) are still learning about the new regulations, as are manufacturers.

Probably the single biggest difference between the MDR and the previous medical device directive is a much greater focus on the post-market elements of devices once in the marketplace. And a key element of that, for example, is the Clinical Evaluation Assessment Report, which is a vital module in your technical documentation submission. Make sure you've got that right. Make sure it's complete. There is some very useful guidance in terms of templates aimed at notified bodies which can help you the manufacturer on the MDCG website. I would thoroughly recommend manufacturers look at these because they provide a very good framework and checklist.

I think I mentioned in my presentation last week, the top areas where we see potential issues in the early submissions we have received. The first by far the most common one is in the Clinical Evaluation Assessment Report (CEAR) arena this requires having a clear post market clinical follow-up (PMCF) element to your documentation submission and make sure its complete. Ensure It covers the full lifetime of the device, that it also reflects all the information that you have. If you're pointing to specific information to support that clinical data, where exactly is it? How do we get to reference data in the right place in your technical documentation? Those are areas that we're really struggling with.
Manufacturers also need to be aware of the requirements for the Periodic Safety Update Reports that we're going to be required 12 months after certificates are issued.

We (BSI) are now going to introduce a completeness check at the front end of the conformity assessment process. So, we can go through and do a relatively topline review, of what's within your technical documentation and see if there's any obvious omissions or gaps with a view that we can flag up front and prevent wasted time when we come and talk to you a few weeks /month later. For example, you don't have a complete PMCF plan. Whilst the differences in clinical requirements from MDD Revision 4 and the MDR are not much as some manufacturers think many manufacturers are still struggling to get to grips with the MDD Revision 4. If you're claiming new or expanded indication(s) for use, make it very obvious in your documentation how we can validate that claim. This will make the review process much more efficient for the notified body, hopefully shorten the review process and get your products to market.

Unleashing the true value potential of AI in healthcare, together

David Dellamonica, VP Value-based health & Innovation lead Europe at **Amgen**

The HTID conference through a great panel discussion of experts discussed the potential of AI to transform how care is delivered. Take away:
Focus on clear unmet medical needs : AI can support improvements in care outcomes, patient experience and access to healthcare services.
Focus on outcomes: Value=(outcome + patient experiences)/(direct cost + indirect cost) : AI can increase productivity and the efficiency of care delivery and allowing healthcare systems to provide more and better care to a greater number of people.

Partner with the ecosystem : AI can help improve the experience of healthcare practitioners. We talk about "Augmented physician", enabling them to spend more time in direct patient care and reducing burnout.
Put the patient at the center : AI can support faster delivery of care, mainly by accelerating diagnosis time, and help healthcare systems manage population health more proactively, allocating resources to where they can have the largest impact.

Finally, Work on challenges: data interoperability, regulatory framework, financing, reimbursement, IT infrastructure, talent management, improve acceptability by education.

«Euronext, the first pan-European listing venue for Life Sciences companies, is naturally partnering with France Biotech and HealthTech For Care to promote the innovative Healthtech sector and its financing. This successful second edition of HTID allowed us to come back on the recent developments of capital markets impacted by COVID-19 and was a great opportunity to share insights with specialized investors.»

Camille Leca, Euronext Chief Operating Officer Listing and Head of Listing France

Contribution of Medtech and Artificial Intelligence to future innovations

Unleashing the true value potential of AI in healthcare, together

Frederic Jean & Mathieu Grajoszex (Digital Medical Hub-APHP)

«Uniting for the digital health of tomorrow»

Supporting academic researchers, developers and Medtech startups to help them on a daily basis is the objective for which the Digital Medical Hub of the Assistance Publique Hôpitaux de Paris (DMH-APHP) was created. From the technological proof of concept to the clinical validation and the medical interest of your product, DMH-APHP offers the opportunity to reassure, prove and seduce investors, partners, users and future customers with the largest European hospital as an ally.

One of the first ambitions of this platform was to bring everyone together around the table in order to be able to support products that meet everyone's needs and demands on inputs and which go up to the business model, on contributions to win-win, pay-for-performance, etc. It was a concrete action to de-risk the establishment of these products, both because they respond more precisely to the hospital demands and also to the creation of value, and by its implantation, to share both risk and value creation since the hospital was also taking a risk in the absence of standard milestones around the evaluation and the market access issues of these medtech products.
We have seen a lot of start-ups with projects coming to us with great technology but not adapted to the real hospital needs. It is like if a pharmaceutical company with a molecule under development was coming to a medical expert with convincing tests on pigs, asking him for a specific opinion in humans. It's not sufficient. We must go beyond the simple technological validations, for example, for an AI diagnostic product, simply demonstrating the specificity and sensitivity of its new diagnostic process is not sufficient.
So, intrinsic technological product performance skills are no longer sufficient in an industrial and scientific context based on what is called medical proof. And for that, you have to make some efforts. We have to look deeply for what the product gives off as advantages, whether clinical, medico-economic, economic in a local system like the hospital or a global medico-economic, in a regulatory system and a global organizational health system.

We have to look for that because the hospital buyers are extremely sensitive to these things. What is the organizational constraint of implantation?, are we going to participate in a well-being in the hospital? in its most important activities? am I convinced of the proposition value?. We are working with several companies on fairly innovative methodologies at this level to search precisely the global added value with the tool versus without the tool. Do we feel better when we feel secure?, do we feel better supported with than without? Do I have an optimized process? Am I more efficient ? faster ? more effective? financially and in my practices? You have to go that far to work on the product value proposition. If we have become something like a pure player, it is by dint of working on the value proposition of products as deeply as possible in order to de-risk their integration. That hospital buyers finally take the step and say yes, it is useful, it seems interesting for my hospital for my activities, I will acquire it and we will also work behind on business models that share the value to create whole economy, optimization.

So, why doing a spin-off of this APHP academic platform? In large part because we need to shine effectively, to be as flexible as possible, to sign or to work with people whom the public hospital is not necessarily used to working with and with whom we have to work with, the startups for example. Flexibility is also on wages, hiring. Everything that cannot be done easily and quickly in the public!
Even if you still need a strong health base to work in our area, to find all the value proposition of these tools and to be able to evaluate these, you have to be either a pharmacist or a doctor, and today we have very few resources in the public sector that offer us the possibility to find people and experts who are both doctors and who have somewhat additional skills, like engineering, business, broad, holistic vision of these subjects. And in addition, we are faced with a growing demand on the part of manufacturers, of start-ups, and of investors to de-risk their products.

And finally added to these points we have a demand increasing of the projects connected to AI. Before last summer we had about 20% of our startups accompanied that integrated what we call, a little more commonly, Augmented Intelligence. Today, more than 80% of projects integrate this Augmented Intelligence with algorithms into their system. The need for AI engineering and technician resources is exponential, it is today absent from the public hospital. However we keep a strong link with the academic platform of the dmh and this is why the Spin-off format is the most efficient way to proceed. All the academic brick is absolutely essential to be able to promote the technological solutions of our startups. So, there is a real complementarity between the two systems, which in fact can be a dimensioning and a structure quite unique both in France and in Europe. We can find similar models in the Boston ecosystem, for example.

« HealthTech Innovation Days are the perfect opportunity to meet the innovation players of today and tomorrow, to build partnerships and collaborations and to share perspectives on key trends like Artificial Intelligence. We will continue to contribute to make HTID a major and attractive event in Europe in 2021. » –
Corinne Blachier-Poisson,VP & GM Amgen France

Contribution of Medtech and Artificial Intelligence to future innovations



Renewed appetite for Medtech markets : VC / Medtech Duo

David Caumartin, CEO at Theraclion

HealthTech Innovation Days is organized around the ecosystem of innovation for biotech and medtech companies.
In 2019, for our first year, we had a participation of nearly 100 entrepreneurs in which there was a small minority of medical device companies. This year, in 2020, we saw that members multiplied by five, including medtech and digital health companies.

I had the chance to participate to HTID Jury to select proven technologyies that were able to be presented to HTID financial attendees. I saw a tremendous number of great innovations in the medtech & in the digital health, that could participate to both conferences and one-to-one meetings hold both in presence or virtually.

A few of my colleagues, have been very interested in seeing initiatives coming, mainly from Europe but also from across the world. Promoting new ideas, applying digital technology or using devices as a way to change health care and bring better tools to patients. So yes, we see a tremendous appetite for growth & innovation. I believe we still have several things to obtain the same interest from pharma business investors.

The medtech European market needs to gain maturity compared to the biotech market, we basically are 10 to 20 years younger and we will catch up but not all at once. However, by looking at what works well, I think we can lean on two major changes to make the medtech and digital health market as attractive as the pharma business.

First, we must have increased experience in the newly developed growth funds for medtech to grow businesses beyond the technology proof into a real, complete, proven solutions that have positive cash flow earnings.
However, we believe analysts should be able to have a better understanding of the development of medtech and digital health, as well as understanding the real challenges and opportunities it presents. It is rarely the case, and we've seen differences in terms of positioning because this is not a simple innovation and new technologies are often frowned upon.

Also, on clinical trials and reimbursements, the understanding of the complete sequence of innovation is required both on the analyst's and the entrepreneur's side to make it a safer investment. So, this is something which I believe is based on a series of small successes and having more senior expertise in the ecosystem will make that market better.

The second big thing is we, at least in France, lack of a comprehensive, predictable policy for market access. You can be as smart as you want with the best patent and clinical development technology, the real value of the health medtech business is in the projected earnings.

Often a technology demonstrates great but doesn't fit some of the funding or the time to demonstrate it is a great financial solution for parties, payors and physicians. More financially proven innovations and early market access policies in France would be a real enabler and accelerator.
I believe some countries are doing it better in Europe than others, of course, and France is probably today not the worse, but it is not far.
We are working very hard with French associations such as, France Biotech, SNITEM, SIDIV and MedTech In France, to promote a new venture. It is inspired by the famous ATU (Autorisations Temporaires d'Utilisation) of the pharma industry. Patient in France will then have early access to innovation that will be paid by the Social Security.

I believe that by improving the financing arm and the payer's process, we can demonstrate earlier disruptive innovations and have a completely different industry valorization in a couple of years?

If I try to summarize, two points are key for accelerating the learning curve.
First, if it's obviously easier to understand what a drug can bring to the patient it's sometimes more difficult to understand the benefits a device, or artificial intelligence can really bring to the patients. This, combined with market access has a big incentive for investors.

I think that the HTID initiative is the catalyst of the two pillars for a real transformation. This event in Paris is a game changer for the European industry and, with EIT Health partnership, is even an even stronger catalyst. The entrepreneurs, as would I, would say those connected both with the payers and the financial institutions could definitively accelerate the maturation time into a better ecosystem.

Contribution of Medtech and Artificial Intelligence to future innovations

Market access for medtech products



Samuel Levy, Founding Partner at Lauxera Capital Partners

I am a physician, medtech entrepreneur and investor.

During my second year of studies at Harvard Medical School, I invented a medical device for weight loss called the Elipse® Gastric Balloon.

With a medical school classmate, I built a company around this technology called Allurion Technologies, and over 10 years, I took the company from an idea on a napkin through commercial sales in more than 30 countries.
One of the most challenging moments of that entrepreneurial journey was transitioning the company from the R&D-stage focused on clinical trial execution to a company creating value through commercial growth.
To achieve this, market access is where the battle is won or lost. You must build a reproducible sales model that creates value for patients, providers and the healthcare system. It must also generate sufficient value for the company to be able to go out and hire the best people and do real marketing. The model can be a cash-pay model or a more traditional reimbursement model. Either way, it must work for all stakeholders to achieve product market fit.

After 10 years, I made the decision that I wanted to leverage my experience to help other growth stage HealthTech companies thrive and grow.
To do that, with two complementary co-founders, I created a new healthcare-focused asset management firm called Lauxera Capital Partners based in Paris. We are actively investing out of a growth buyout vehicle focused on European health technology companies. We don't take scientific risk. We don't take clinical risk. We focus on commercial risk and we create value through topline revenue growth.

I focus every day on trying to validate the product market fit of health technology products within Europe, the US and the Chinese health care systems. It is mission critical to get regulatory approval, but that step is necessary, not sufficient. You must be able to get paid for selling your great innovation.

This element of the entrepreneurial journey is often overlooked during early company creation. When entrepreneurs create medical technology companies, often the impetus for incorporating the business is the technology itself: a new material, algorithm, or production process. Technology enables innovation, but pure technology is almost never the core reason why products ultimately succeed in the marketplace.

A key takeaway from the market access panel at HTID was the absolute necessity of thinking about market access strategies at the very beginning of the innovation cycle. You must know if there's an existing reimbursement code that can be leveraged for your technology and if there's not, you have to put in place a clear strategy for how you're going to unlock it. If there isn't an approach to market access that is attractive and available on an investible timescale, innovate something else.

Let me share a specific case: a Danish company called Reapplix. Reapplix is in the Lauxera portfolio. This is a regenerative medicine business that has developed an innovative therapeutic device in the diabetic foot ulcer space. It took the company ten years to develop the product and validate its clinical utility through a well-designed, randomized, controlled clinical trial. Through some early market research, the company realized that 90 percent of the global advanced biologic wound care market is in the United States. It was therefore critical for the company to develop a strategy for market access in the US.
The Reapplix team observed that with 85% of diabetic foot ulcer patients over the age of 65, Medicare was the key reimbursement battle to win. Implementation of a Medicare reimbursement code took the company three years following FDA approval. It goes without saying that three years is an eternity for "commercial stage," venture-backed companies without substantial sales. With an attractive Medicare code in place, the company has finally been able to start successfully driving US commercialization. It was exactly at this juncture that Lauxera made the decision to deploy capital into the business.

PROGRAM 2020

https://htid-paris.streameo.fr

October 5th – Salon Etoile

12:50 - 2:00 PM : Grand Opening & Venture Centre of Excellence Programme Launch

Speakers:
Jan-Philipp Beck, CEO EIT Health
Jean-Marc Bourez, Managing Director of EIT Health France and Head of the VCoE
Thierry Breton, Commissioner at European Commission, Internal Market
Hubert Cottogni, Director and Head of Mandate Management
Alexandra Dublanche, Representative of Ile-De-France Region
Nicolas Dufourcq, CEO at Bpifrance
Maryvonne Hiance, President of HealthTech For Care
Franck Mouthon, President France Biotech and CEO of Theranexus

2:00 - 3:00 PM : Keynote - Economic impact of Covid-19 on the healthtech ecosystem

Moderated by Christian Pierret, Former French Minister of Industry
Speakers :
Philippe Aghion, Professeur at Collège de France and at London School of Economics, member of Société économétrique and american academy of arts and sciences.
Jan-Philipp Beck, CEO EIT Health
Thierry Breton, Commissioner at European Commission, Internal Market
Stewart Cole, Managing Director at l'Institut Pasteur

3:15 - 4:00 PM : Winning together : Successful corportate, healthtech companies and academic collaborations

Facilitator : Paul Barrett
Speakers :
1. Donna Armentano, Executive Director External R&D Innovation and Global Head Gene Therapy at Pfizer & Jean-Philippe Combal, PharmD, Ph.D co-founder & CEO at Vivet Therapeutics
2. Pr Jean-Yves Blay, Managing Director at Centre Léon Bérard and Président of Unicancer & Dominique Costantini, Chairman and Director of early development chez OSE Immunotherapeutics
3. Amaury Martin, Director, Technology transfer and Industrial partnerships, Institut Curie. & Luigi Ravagnan, Director, Strategic Collaborations, Global Medical, Bristol Myers Squibb

4:00 - 5:00 PM : Why & How setting an efficient corporate governance in innovative firms to support growth ?

Moderated by Lilian Stern, founder of Stern IR
Speakers :
Elsy Boglioli, CEO of Bio-up
Virginie Lleu, Founder and Executive director of L3S Partnership
Cédric Moreau, Partner at Sofinnova Partners
Nawal Ouzren, CEO of Sensorion

5:30 - 6:30 PM : Impact of the Covid-19 crises on financing opportunities and risks

Moderated by : Alain Pujol, Angels Santé Board member
Speakers :
Nissim Darvish, Partner Orbimed (Tel Aviv)
Marc Le Bozec, Fund Manager at Financières Arbevel
Camille Leca, Head of Listing France at Euronext
Philippe Monteyne, Partner @Fund+
Antoine Papiernik, Chairman & Managing Partner at Sofinnova Partners

6:30 - 7:00 PM : Value creation through smart partnerships. The biotech & pharma perspectives

Facilitator : Paul Barrett
Speakers :
Jean-Paul Kress, CEO at MorphoSys AG
Alban De La Sablière, SVP Global Head of Sanofi Partnering.

7:15 PM : Cocktail Reception

Agnès Pannier-Runacher, Minister Delegate to the Minister of the Economy, Finance and Recovery, in charge of Industry

PROGRAM 2020

https://htid-paris.streameo.fr

October 5th – Salon Lobby

2:00 - 2:30 PM : New EU regulations in the Medtech sector

Moderated by Alexandre Regniault, Lawyer at Simmons & Simmons

Speakers :

Marc Julien, Co-CEO Diabeloop

Lionel Dreux, President at GMED

Stéphane Piat, Managing Director at Carmat

Gary Slack, Senior Vice President Global Medical Devices at BSI.

2:30 - 3:00 PM : Medtech - Market Access

Moderated by Samuel Levy, Founding Partner at Lauxera Capital Partners

Speakers :

Graeme Brookes, CEO at Reapplix

Whitney Cypes, Vice President Global Marketing at Allurion Technologies

3:30 - 4:30 PM : VCoE : Innovating for Innovators

Speakers :

Jean-Marc Bourez, EIT Health France Managing Director and Head of the VCoE

Rémi Charrier, Global Head of Institutional Client Relationship, European Investment Fund

Stephan Christgau, Founding Partner, Eir Ventures

VP Value-based health & Innovation lead Europe, Amgen

Marc Julien, CEO, Diabeloop

Tomasz Kozlowski, Head of Mandate and Product Development, European Investment Fund

Patric Gresko, Head of Division - Innovation and Technology Investments, European Investment Fund

Henrik Matthies, Managing Director, Health Innovation Hub (HIH) Germany

Anne Osdoit, Partner, Sofinnova Partners (MDStart Fund)

Thomas Trailov, Director Strategy & Insights | World Business Line Healthcare, Air Liquide Santé International

4:30 - 5:00 PM : Keynote on entrepreneur & VC success (Corvidia Therapeutics learning experience)

Facilitator :Paul Barrett

Speakers :

Marc de Garidel, Chief Executive Officer at Corvidia Therapeutics

Graziano Seghezzi, Managing Partner at Sofinnova Partners

5:30 - 6:30 PM : Opportunities and challenges for Innovative healthtech companies in Europe (Bio-Deustchland & France Biotech)

Moderated by

Pierre Courteille, Chief Commercial Officer & Vice President Business Development at Abivax and VP at France Biotech

Oliver Schacht ,PhD, Bio Deutschland Presdient

Speakers

Pierre Courteille, Chief Commercial Officer & Vice President Business Development at Abivax and VP at France Biotech

Jack Elands, CEO Emergence AG

Mondher Mahjoubi, CEO Innate Pharma

Oliver Schacht ,PhD, Bio Deutschland Presdient

Jan Schmidt- Brand, CEO/CFO Heidelberg Pharma

6:30 - 7:15 PM : Opportunities in setting stronger relationship between, health industry & patient association

Speakers :

Dominique Pon, Minister Collaborator - Strategic Manager of the digital transformation in health & Managing Director of the Clinique Pasteur in Toulouse

Gérard Raymond, President of France Assos Santé

PROGRAM 2020

https://htid-paris.streameo.fr

October 6th - Salon Etoile

8:30 - 11:30 AM : Cellular therapy & gene therapy: where do we stand, what perspectives?

Moderator : Christian Policard, Founding Partner at Biotech Développement Conseils
Chairmen : Pr Fabrice André , Head of Research, Gustave Roussy Institute, Villejuif &Frederic Revah, CEO, Genethon
Speakers :
Sebastian Amignorena, Research Director at Institut Curie, CNRS
Nathalie Cartier-Lacave, Director, NeuroGenCell Brain Lab and Spine Institute (ICM), Pitie-Salpetriere Hospital, Paris
Marina Cavazzana, Head of the Biotherapy Department at Necker Hospital and Imagine Institute
Patrick Henno, Co-founder of EMERCell
Mohamad Mohty, Head of the Hematology and Cellular Therapy Department at Saint-Antoine Hospital and University Pierre & Marie Curie
Jean-Antoine Ribeil, Medical Director in Medical Affair Department at Bluebird Bio

11:30 - 12:15 PM : Renewed appetite for Medtech markets : VC/ Medtech duo

Moderated by André Michel Ballester
Speakers
Scott Bardo, Senior Healthcare Analyst at Berenberg Bank
Tim Haines, Chairman and Managing Partner at Abingworth
Sacha Loiseau, Venture Partner at Elaia
Bertin Nahum, Founder and President of Quantum Surgical

1:15 -2:30 PM : Facing Covid-19 : challenges for Biotechs and Pharmas

Moderated by Eric Falcand, Global Head of Business Development and Licensing, Servier &Christian Policard, Founding Partner at Bio Developpement Conseil (France)
Speakers :
Hugues Bultot, Co-founder and Chief Executive Officer Univercells
Christian Deleuze, Chairman of the Research & Innovation Commission at Leem
Rahim Fandi, Chief Medical Officer, Oxford Biotherapeutics
Laurent Levy, Co-founder and Chief Executive Officer Nanobiotix
Olivier Madec, Global Head of M&A and Venture Investments Servier
Frédérik Rothenburger, Managing Director at Lazard
Jacques Volckmann, Head R&D France, at Sanofi

2:45 - 3:45 PM : Manufacturing challenges and step forwards in new therapies

Facilitator : Paul Barrett
Speakers :
Serge Braun, Scientific Director at AFM Telethon
Frédéric Collet, Président at Leem (Les Entreprises du Médicament)
Richard Snyder, Vice President, Science and Technology Pharma Services, Viral Vector Services at ThermoFisher
Antoine Jourdan, Health Project Director at Direction Générale des Entreprises

4:15 - 5:30 PM : Amgen & EIT Health plenary session, Unleashing the true potential of AI in healthcare, together

Facilitator : Paul Barrett
Speakers :
Jean-Marc Bourez, Managing Director & Head of the VCoE, EIT Health France
David Dellamonica, Head Value Based Partnership & Digital innovation, DEEP AI Platform founder, Amgen Europe
Frederic Jean, Co-developer, Digital Medical Hub AP-HP
Henrik Matthies, Managing Director, Health Innovation Hub (HIH, Germany)
Philippe Menu, CMO SophiA Genetics
Karl Neuberger, Partner at Quantmetry
Arnaud Rosiers, CEO, Implicity
Stéphane Tholander, CEO & Co-Founder of Cibiltech
Stéphanie Trang, Managing Director of the AI for Health Initiative at Start-up Inside
Nicolas Villain, Director of the Research Department and AI HUB, Philips Healthcare

5:30 - 6:30 PM : Closing ceremony & Cocktail

PROGRAM 2020

https://htid-paris.streameo.fr

October 6th – Salon Lobby

8:45 - 9:45 AM : VCoE : EIF Market Insights (VCoE restricted plenay)

10:15 AM - 12:15 PM : VCoE : Shaping the Member Community Vision and Discussion (VCoE restricted plenary)

1:15 - 2:15 PM : Key Collaboration and Financing Issues during the Covid-19 Pandemic

Moderator
Paul Barrett

Speakers :
Anne-Charlotte Rivière, Partner, Paris at Dechert
David Schulman, Partner, Washington D.C. at Dechert

2:45 - 3:45 PM : Behavior of stakeholders in high volatility innovative markets like HealthTech

Moderated by
Pierre Courteille, Chief Commercial Officer & Vice President Business Development at Abivax and VP France Biotech

Speakers :
Professor Randall Kroszner, Deputy Dean for Executive Programs and Norman R. Bobins Professor of Economics at University of Chicago Booth
Professor Scott Meadow, Clinical Professor of Entrepreneurship at University of Chicago Booth

4:15 - 5:30 PM : Creating a New Culture of Innovation through Collaboration: the Bridging Academia with Industry Paradigm Shift

Moderated by
Gabriela Apiou, PhD, Director of Strategic Alliances at Mass General Research Institute and Assistant Professor of Dermatology at Harvard Medical School
& Robert Tepper, MD, Partner at Third Rock Ventures and Member of the Mass General Research Institute Advisory Council.

Speakers :
Patrick Fortune, PhD, Vice President, Market Sector at Mass General Brigham Innovation Office
Saptarsi Haldar, MD, Vice President of Research and Head of Cardometabolic Discovery at Amgen
Anthony Rosenzweig, MD, Chief of the Cardiology Division at Mass General Hospital

5:30 - 6:30 PM : Closing ceremony & Cocktail

Replays of the HTID round tables : https://htid-paris.streameo.fr

About

About HealthTech For Care

The HealthTech For Care endowment fund, launched by France Biotech, is designed to support and promote access to care for all and, more specifically, to new medical technologies and drugs. The missions of the endowment fund are structured around three main areas: Supporting the development of the entire health ecosystem, accelerating the development of innovative therapies and treatments, and promoting better access to healthcare for patients in the French healthcare system and more widely throughout Europe. HealthTech For Care is administrated by Maryvonne Hiance, Elsy Boglioli, David Caumartin, Pierre Courteille, Eric Falcand, Marc Le Bozec, Cédric Moreau, Franck Mouthon, Christian Pierret and Christian Policard.

About EIT Health

Europe faces a turning point in health. An ageing population, the rising burden of chronic disease, and growing multi-morbidity are all placing pressure on health systems across Europe.
EIT Health is a vast, vibrant community of world leading health innovators backed by the European Union. Working across borders, our network connects approximately 150 world-class partner organisations, as well as entrepreneurs, start-ups and SMEs from the worlds of business, research, education and healthcare delivery. Our aim is to answer the biggest health challenges Europe faces and we believe that life changing innovation happens when these worlds meet and collaborate. That's why we call this the 'knowledge triangle'.
From our headquarters in Munich, six regional Innovation Hubs and InnoStars cluster, which brings together organisations from regions in which the overall pace of innovation is more moderate, we provide an ecosystem in which fresh thinking can thrive. Our Regional Innovation Scheme further expands our presence in 13 countries across Central, Eastern and Southern Europe. EIT Health also leads the development of the EIT Hub in Israel, which connects innovators across Europe to other key thriving ecosystems beyond the EU.
EIT Health is supported by the European Institute of Innovation and Technology (EIT), a body of the European Union. Our ambition is to enable people in Europe to live longer, healthier lives by transforming businesses and delivering new products and services that can progress healthcare in Europe and strengthen our economy.

EIT Health: Together for healthy lives in Europe.
For more information visit: www.eithealth.eu

About France Biotech

Founded in 1997, France Biotech is an independent association that brings together the country's leading innovative health companies and their expert partners. As a leader in health innovation and a privileged intermediary with public authorities in France and Europe, France Biotech's mission is to support the development of this industry in France, by improving the tax, legal, regulatory and managerial environment in which these companies operate and by advocating for their recognition as a leading-edge industry. France Biotech also aims to turn French innovative health technology companies into world leaders capable of designing and developing new innovations quickly and make them available and accessible to patients. France Biotech has founded and is developing the « HealthTech For Care » fund to strengthen the ability to federate, structure and encourage cooperation between the various stakeholders in the health tech sector in France and Europe. France Biotech is chaired since September 2019 by Franck Mouthon, CEO of Theranexus...

HTID 2 KEY NUMBERS

2 Days in Paris and in virtual
October 5&6, 2020

Hybrid event

Support
From Europe and France

780
Participants

19
Conferences with experts and KOLs

1000
Private meetings

15
Pharmaceutical groups

300
Investors from all around the world

150
HealthTech Companies

Looking forward to seeing you for HTID 3 in 2021 !

Thanks to our partners

Platinium

SERVIER

Super Gold

SANOFI

Gold

AMGEN INNOVATIONS
LA SCIENCE & L'HUMAIN

Bristol Myers Squibb™

leem
les entreprises du médicament

Pfizer

SOFINNOVA
PARTNERS FOR LIFE

Silver

FINANCIÈRE ARBEVEL

BNP PARIBAS
The bank for a changing world

bpifrance

INVEST SECURITIES

IPSEN
Innovation for patient care

Bronze

BDC

Dechert LLP

EURONEXT

Social Media & Contacts

HealthTech Innovation Days
https://www.linkedin.com/company/htid

HealthTech Innovation Days
https://twitter.com/HTID_Paris

HealthTech For Care
http://htfc-eu.com

HealthTech For Care

eit Health

EIT Health is supported by the EIT, a body of the European Union

Estelle Metzger
Project Manager Junior
estelle.metzger@htfc-eu.com
+33 (0)6 38 03 80 60

Solene Goupy
Communication Manager
solene.goupy@htfc-eu.com
+33 (0)6 38 03 80 19

Nathalie Donne
Senior Advisor Manager
nathalie.donne@insead.eu
06 67 67 44 97